ProPhase Labs - PRPH Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRPH, but not buy additional shares or sell existing shares.
View PRPH analyst ratings or view top-rated stocks.

2 brokerages have issued 1-year price targets for ProPhase Labs' stock. Their PRPH share price forecasts range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 93.1% from the stock's current price.
View analysts price targets for PRPH or view top-rated stocks among Wall Street analysts.

ProPhase Labs' stock was trading at $9.63 on January 1st, 2023. Since then, PRPH shares have decreased by 19.3% and is now trading at $7.77.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our PRPH earnings forecast.

ProPhase Labs, Inc. (NASDAQ:PRPH) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of $0.07 by $0.33. The company had revenue of $9.47 million for the quarter, compared to analyst estimates of $9.08 million. ProPhase Labs had a net margin of 21.58% and a trailing twelve-month return on equity of 42.50%. During the same period in the prior year, the company earned ($0.05) earnings per share.

ProPhase Labs declared a dividend on Friday, May 13th. Stockholders of record on Wednesday, May 25th will be given a dividend of $0.30 per share on Friday, June 3rd. The ex-dividend date is Tuesday, May 24th.
Read our dividend analysis for PRPH.

First Trust Dow Jones Select Microcap Index Fund holds 31,581 shares of PRPH stock, representing 0.16% of its portfolio.

2 employees have rated ProPhase Labs Chief Executive Officer Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among the company's employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include VIVUS (VVUS), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Fulcrum Therapeutics (FULC), Novus Therapeutics (NVUS), Onconova Therapeutics (ONTX) and Recro Pharma (REPH).

ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."

ProPhase Labs' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.39%), Geode Capital Management LLC (0.76%), Marshall Wace LLP (0.55%), Navellier & Associates Inc. (0.44%), Bank of Montreal Can (0.42%) and American Century Companies Inc. (0.41%). Insiders that own company stock include Jason Michael Barr, Louis Md Gleckel and Ted William Karkus.
View institutional ownership trends.

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRPH stock can currently be purchased for approximately $7.77.

ProPhase Labs (NASDAQ:PRPH) has a market capitalization of $126.50 million and generates $79.04 million in revenue each year. The company earns $6.27 million in net income (profit) each year or $1.82 on an earnings per share basis.

ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The official website for the company is www.prophaselabs.com. The company can be reached via phone at (215) 345-0919, via email at ir@prophaselabs.com, or via fax at 215-345-5920.